ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Catalyst Pharmaceutical Partners, Inc. 

355 Alhambra Circle, Suite 1500

Coral Gables  Florida  33134  U.S.A.
Phone: 305-529-2522 Fax: 305-529-0933


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Second Quarter 2014 Financial Results 8/14/2014 7:37:38 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Provides Updates On Progress Of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 8/11/2014 7:37:15 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present At The JMP Securities 2014 Healthcare Conference 6/19/2014 10:23:51 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Set To Join Russell Microcap® Index 6/18/2014 1:44:24 PM
Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present At The Jefferies and Co. 2014 Global Healthcare Conference 5/29/2014 9:23:41 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces First Quarter 2014 Financial Results And Provides Corporate Update 5/16/2014 9:21:59 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Initiation Of An Expanded Access Program To Provide Firdapse At No Cost To U.S. Patients With Lambert-Eaton Myasthenic Syndrome 4/23/2014 9:34:46 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Closing Of Previously Announced Public Offering 4/8/2014 2:07:17 PM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Prices Public Offering Of Common Stock 4/3/2014 7:54:41 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Completion Of Enrollment In Pivotal Phase 3 Trial Of Firdapse™ In Patients With Lambert-Eaton Myasthenic Syndrome 4/1/2014 9:50:20 AM
12345678910...